The Female Contraception drugs in development market research report provides comprehensive information on the therapeutics under development for Female Contraception, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Female Contraception. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Female Contraception and features dormant and discontinued products.
GlobalData tracks 38 drugs in development for Female Contraception by 38 companies/universities/institutes. The top development phase for Female Contraception is preclinical with 18 drugs in that stage. The Female Contraception pipeline has 31 drugs in development by companies and seven by universities/ institutes. Some of the companies in the Female Contraception pipeline products market are: Lyndra Therapeutics, Dare Bioscience and Adare Pharma Solutions.
The key targets in the Female Contraception pipeline products market include Progesterone Receptor, Estrogen Receptor, and Human Immunodeficiency Virus Surface Protein gp120.
The key mechanisms of action in the Female Contraception pipeline product include Progesterone Receptor Agonist with 14 drugs in Pre-Registration. The Female Contraception pipeline products include seven routes of administration with the top ROA being Oral and five key molecule types in the Female Contraception pipeline products market including Small Molecule, and Monoclonal Antibody.
Female Contraception overview
Contraception (birth control) prevents pregnancy by interfering with the normal process of ovulation, fertilization, and implantation. There are many contraceptive methods which include implants and injections, intrauterine devices (IUDs), pills and vaginal rings, barrier methods, sterilization, and “natural” methods. Contraception generally works by preventing sperm from reaching and fertilizing an egg (barrier and IUD methods), preventing an egg from being released every month (hormones), blocking the reproductive function (sterilization), and preventing a fertilized egg from implanting in the uterus (hormones).
For a complete picture of Female Contraception’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
